Beyond Prostate-Specific Antigen Response: Could 18 F-FDG PET Refine Patient Selection for Rechallenge with [ 177 Lu]Lu-PSMA-617?
TO THE EDITOR: I read with great interest the recently published RE-LuPSMA protocol by Nikitas et al. describing a prospective phase 2 study evaluating retreatment with [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer who previously benefited from prostate-
Authors
- Alev Çinar
Publication Details
- Journal
- Journal of Nuclear Medicine
- Published
- 2026-10-29
- DOI
- https://doi.org/10.2967/jnumed.126.273292
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00